Anti-BCMA-Anti-CD3-Avi-His-Tag is a purified recombinant human bispecific molecule with T cell Engager. This bispecific molecule has been tested for specific activity in both ELISA binding assay to BCMA-biotin and functional reporter assay using NFAT-luc reporter Jurkat cell line (BPS Bioscience #60621) in the presence of BCMA-CHO cells (BPS Bioscience #79500-H).
ELISA assay shows specific binding of anti BCMA-anti CD3 when the ELISA plate is coated with anti BCMA-anti CD3 molecule and exposed to a BCMA Biotin (BPS Bioscience #79467-1) titration. *Not all lots have been tested for enzyme activity.
Activation of NFAT Reporter Jurkat cells by anti BCMA-anti CD3 bispecific molecule in the presence of BCMA-CHO cells. *Not all lots have been tested for enzyme activity.
Anti-BCMA-Anti-CD3:Mouse BCMA Biotin Binding Assay *Not all lots have been tested for enzyme activity.
Ni-NTA affinity purification of the His-tag protein from HEK293 cells.
Format
Aqueous buffer solution.
Formulation
8 mM phosphate pH 7.4, 110 mM NaCl, 2.2 mM KCl, and 20% glycerol
MW
57 kDa + glycans
Amino Acids
1-497(end)
Glycosylation
This protein runs at a higher MW by SDS-PAGE due to glycosylation.
UniProt #
Q02223
Tag(s)
C-terminal Avi-His-Tag
Background
B-cell maturation antigen (BCMA), also known as tumor necrosis factor receptor superfamily member 17 (TNFRSF17), is a protein encoded by the TNFRSF17 gene. TNFRSF17 is a cell surface receptor of the TNF receptor superfamily that recognizes B-cell activating factor (BAFF). BCMA is preferentially expressed in mature B lymphocytes and also on Multiple Myeloma (MM) cells. Upregulation of BCMA also correlates with disease burden and prognosis in multiple myeloma. This bispecific molecule binds to BCMA on cancer cells and CD3 on T cells simultaneously, thus bringing T lymphocytes closer to the cancer cells. The binding event potentiates unstimulated T cells and induces direct cytotoxicity against BCMA+ cancer cells.
Storage/Stability
Stable for at least 12 months at -80°C.
Assay Conditions
The protein was validated by measuring anti-BCMA-anti-CD3 binding to Mouse BCMA in ELISA assay. The anti-BCMA-anti-CD3 (BPS Bioscience #100689) was coated onto a white 96-well plate overnight at 4°C (50 µl/well at a concentration of 4 µg/ml in PBS). The plate was washed 3 times with Immuno Buffer 1 (BPS Bioscience #79311) and blocked using 100 µl of Blocking Buffer 2 (BPS Bioscience #79728) for 1 hour at room temperature. After removing the blocking buffer, 50 µl/well of purified Mouse BCMA Fc Biotin, serially diluted in Blocking Buffer 2, was added for 1 hour at room temperature. After 3 more washes, the plate was incubated with Streptavidin-HRP (BPS Bioscience #79742), washed, and incubated with the Chemiluminescence ECL substrates (BPS Bioscience #79670). The plate was read, and the Blank value was subtracted from all values.
Applications
This product is for research use only. It is not suitable for human diagnostic or therapeutic use. The anti-BCMA-anti-CD3-Avi-His-Tag can be used for studying BCMA+ cancer cell-mediated T cell activation, using either primary T cells or reporter cell lines such as NFAT-luc-Jurkat cells (BPS Bioscience #60621).
Powered by Bioz
